Zr-89 as a promising radionuclide and it's applications for effective cancer imaging

SARCAN E. T., SİLİNDİR GÜNAY M., Ozer A. Y., Hartman N.

JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol.330, no.1, pp.15-28, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 330 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1007/s10967-021-07928-0
  • Journal Name: JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, EMBASE, Food Science & Technology Abstracts, INSPEC, Metadex, Pollution Abstracts, Public Affairs Index, Veterinary Science Database, Civil Engineering Abstracts
  • Page Numbers: pp.15-28
  • Keywords: Zr-89, immuno-PET, Zr-89 radiolabelling, Zr-89-mAb, Zr-89-gold NPs, POSITRON-EMISSION-TOMOGRAPHY, BIFUNCTIONAL CHELATING-AGENT, IMMUNO-PET, MONOCLONAL-ANTIBODIES, CLINICAL TRANSLATION, RADIATION-DOSIMETRY, GOLD NANOPARTICLES, DRUG-DELIVERY, TUMOR UPTAKE, NO-CARRIER
  • Hacettepe University Affiliated: Yes

Abstract

Molecular imaging using PET plays an important role for the diagnosis of different diseases. Immuno-PET combines the utilization of PET radionuclides and antibodies/proteins/peptides, presenting a popular method for imaging of different diseases, including cancer. Zr-89 is an attractive radiometal for immuno-PET but far from ideal due to its high radiation dose for the patients. However, its long half-life is sometimes advantageous and suitable for labelling antibodies, proteins and other biomolecules. This review compiles opportunities and applications for using Zr-89 in preclinical and clinical practice. It contains either results from for its production, preclinical and clinical studies.